This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Nakamura, Yusuke
| Item Type | Name |
|
Concept
|
Testis
|
|
Academic Article
|
Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis.
|
|
Academic Article
|
Involvement of RQCD1 overexpression, a novel cancer-testis antigen, in the Akt pathway in breast cancer cells.
|
|
Academic Article
|
Involvement of G-patch domain containing 2 overexpression in breast carcinogenesis.
|
|
Academic Article
|
Lysyl 5-hydroxylation, a novel histone modification, by Jumonji domain containing 6 (JMJD6).
|
|
Academic Article
|
Oncogenic role of NALP7 in testicular seminomas.
|
|
Academic Article
|
Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer.
|
|
Academic Article
|
Identification of a nuclear protein, LRRC42, involved in lung carcinogenesis.
|
|
Academic Article
|
Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma.
|
|
Academic Article
|
Isolation of LEM domain-containing 1, a novel testis-specific gene expressed in colorectal cancers.
|
|
Academic Article
|
Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas.
|
|
Academic Article
|
PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer.
|
|
Academic Article
|
Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer.
|
|
Academic Article
|
HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
|
|
Academic Article
|
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.
|